Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), Encompass Health (EHC) and Annexon Biosciences (ANNX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Beam Therapeutics (BEAM), Encompass Health (EHC) and Annexon Biosciences (ANNX) with bullish sentiments.

TipRanks Welcomes a New ETF – NYSE:RANK

• TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
• RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.

Beam Therapeutics (BEAM)

In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Beam Therapeutics, with a price target of $47.00. The company’s shares closed last Wednesday at $36.88.

According to TipRanks.com, Stranahan is a 5-star analyst with an average return of 10.8% and a 54.9% success rate. Stranahan covers the Healthcare sector, focusing on stocks such as Recursion Pharmaceuticals, Perspective Therapeutics, and Janux Therapeutics Inc. ;'>

Currently, the analyst consensus on Beam Therapeutics is a Strong Buy with an average price target of $52.91, which is a 45.2% upside from current levels. In a report issued on July 7, H.C. Wainwright also reiterated a Buy rating on the stock with a $80.00 price target.

See the top stocks recommended by analysts >>

Encompass Health (EHC)

Barclays analyst Andrew Mok CFA maintained a Buy rating on Encompass Health today and set a price target of $140.00. The company’s shares closed last Wednesday at $110.25.

According to TipRanks.com, CFA is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -4.7% and a 51.9% success rate. CFA covers the Healthcare sector, focusing on stocks such as Aveanna Healthcare Holdings, Brookdale Senior Living, and Alignment Healthcare. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Encompass Health with a $136.25 average price target, representing a 23.9% upside. In a report issued on June 26, Truist Financial also reiterated a Buy rating on the stock with a $140.00 price target.

Annexon Biosciences (ANNX)

Needham analyst Joseph Stringer maintained a Buy rating on Annexon Biosciences today and set a price target of $11.00. The company’s shares closed last Wednesday at $5.96.

According to TipRanks.com, Stringer is a 5-star analyst with an average return of 26.9% and a 51.7% success rate. Stringer covers the Healthcare sector, focusing on stocks such as Phathom Pharmaceuticals, Rhythm Pharmaceuticals, and Vertex Pharmaceuticals. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Annexon Biosciences with a $10.00 average price target.

Read More on BEAM:

Disclaimer & DisclosureReport an Issue

• TD Cowen says arbitration decision removes overhang for Prime Medicine’s PM647
• Resolution in favor of Prime has limited impact to Beam, says BofA
• Prime Medicine reports positive resolution to arbitration with Beam Therapeutics
• Ambarella, Beam, United Micro, Hyperscale Data, Atai Beckley Shocking Insider Moves
• Beam Therapeutics announces U.S. FDA clearned IND application for BEAM-304